{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:52:24Z","timestamp":1791208344974,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574180"],"award-info":[{"award-number":["82574180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic HPV vaccines (TxVs) may complement existing cervical cancer prevention strategies, particularly for women already infected with HPV who derive limited benefit from prophylactic vaccination. As China advances toward the WHO 90\u201370\u201390 cervical cancer elimination targets, understanding the potential health impact of therapeutic vaccines under varying implementation scenarios is critical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a two-stage hybrid model combining a dynamic HPV transmission model with a natural history model of HPV-related disease progression to project the long-term health impact of therapeutic HPV vaccines in China from 2025 to 2125. Two vaccine types aligned with WHO Preferred Product Characteristics were evaluated: one targeting HPV infection clearance (TxV1) and one targeting treatment of cervical intraepithelial neoplasia (CIN) grade 2 or 3 (TxV2). Vaccination was modelled under two use cases: population-based delivery and integration into existing national screening programmes. Outcomes included cervical cancer cases and deaths averted, relative reductions compared with no therapeutic vaccination, age-standardised incidence, and the projected year of elimination. One-way and probabilistic sensitivity analyses evaluate model uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base case, screening-integrated TxV1 (Use Case 2) could avert up to 834.0 thousand cervical cancer cases (12.7% reduction) and accelerate elimination by 11 years, while population-based TxV1 could avert 169.6\u2013474.0 thousand cases (2.6\u20137.2% reduction). TxV2 showed more modest effects (2.4\u20137.4% reduction) and was highly sensitive to conventional CIN treatment coverage. Therapeutic vaccine impact was greater in scenarios with limited scale-up of prophylactic vaccination. Vaccine efficacy, coverage, genotype spectrum, and rollout timing were key drivers of impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Therapeutic HPV vaccines with substantial efficacy could reduce the cervical cancer burden in China, particularly during the transition toward full-scale prophylactic vaccination and screening. These findings support continued investment in therapeutic HPV vaccine development and provide evidence to inform national strategy planning aligned with elimination goals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-05050-0","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:13:42Z","timestamp":1783401222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential health impact of therapeutic HPV vaccines in China: a modeling study"],"prefix":"10.1186","volume":"24","author":[{"given":"Chenghao","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"3","key":"5050_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"9590","key":"5050_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890\u2013907.","journal-title":"Lancet"},{"issue":"9895","key":"5050_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","volume":"382","author":"EJ Crosbie","year":"2013","unstructured":"Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889\u201399.","journal-title":"Lancet"},{"key":"5050_CR4","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative. Accessed 2 Feb 2025."},{"key":"5050_CR5","unstructured":"The State Council of the People\u2019s Republic of China. China plans to add HPV vaccine to national immunization program, expanding coverage for females. https:\/\/english.www.gov.cn\/news\/202509\/11\/content_WS68c27731c6d00fa19f7a25cf.html. Accessed 12 Sep 2025."},{"issue":"1","key":"5050_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40249-023-01136-6","volume":"12","author":"X-L Zhao","year":"2023","unstructured":"Zhao X-L, Hu S-Y, Hu J-W, Wang H-H, Wen T-M, Feng Y-S, et al. Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward. Infect Dis Poverty. 2023;12(1):86.","journal-title":"Infect Dis Poverty"},{"issue":"19","key":"5050_CR7","first-page":"413","volume":"6","author":"C Junlei","year":"2023","unstructured":"Junlei C, Zhaonan Z, Weiyi P, Yifan S, Lu Z, Li L, et al. Estimated Human Papillomavirus Vaccine Coverage Among Females 9\u201345 Years of Age \u2014 China, 2017\u20132022. China CDC Wkly. 2023;6(19):413\u20137.","journal-title":"China CDC Wkly"},{"key":"5050_CR8","unstructured":"World Health Organization. WHO vaccine position papers. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/position-papers. Accessed 1 Aug 2025."},{"issue":"6","key":"5050_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1634\/theoncologist.2014-0303","volume":"20","author":"B Wang","year":"2015","unstructured":"Wang B, He M, Chao A, Engelgau MM, Saraiya M, Wang L, et al. Cervical Cancer Screening Among Adult Women in China, 2010. Oncologist. 2015;20(6):627\u201334.","journal-title":"Oncologist"},{"issue":"48","key":"5050_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.46234\/ccdcw2022.217","volume":"4","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhong Y, Wang L, Bao H, Huang Z, Zhao Z, et al. Cervical Cancer Screening Coverage - China, 2018\u20132019. China CDC Wkly. 2022;4(48):1077\u201382.","journal-title":"China CDC Wkly"},{"issue":"10","key":"5050_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.46234\/ccdcw2025.052","volume":"7","author":"M Zhang","year":"2025","unstructured":"Zhang M, Wang L, Zhang X, Li C, Zhao Z, Yu M, et al. Cervical Cancer Screening Rates Among Chinese Women - China, 2023\u20132024. China CDC Wkly. 2025;7(10):321\u20136.","journal-title":"China CDC Wkly"},{"key":"5050_CR12","doi-asserted-by":"publisher","first-page":"e078641","DOI":"10.1136\/bmj-2023-078641","volume":"386","author":"F Zhao","year":"2024","unstructured":"Zhao F, Lang J, Qiao Y, Zhu L. How can China achieve WHO\u2019s 2030 targets for eliminating cervical cancer? BMJ. 2024;386:e078641.","journal-title":"BMJ"},{"issue":"02","key":"5050_CR13","first-page":"220","volume":"23","author":"C Zhao","year":"2022","unstructured":"Zhao C, Bi H, Zhao Y, Geng L, Liu J, Shen D, et al. Chinese Expert Consensus on the Management of High-Grade Cervical Epithelial Lesions. Chin J Clin Obstet Gynecol. 2022;23(02):220\u20134.","journal-title":"Chin J Clin Obstet Gynecol"},{"issue":"11","key":"5050_CR14","first-page":"CD012847","volume":"11","author":"M Kyrgiou","year":"2017","unstructured":"Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017;11(11):CD012847.","journal-title":"Cochrane Database Syst Rev"},{"key":"5050_CR15","doi-asserted-by":"publisher","first-page":"i3633","DOI":"10.1136\/bmj.i3633","volume":"354","author":"M Kyrgiou","year":"2016","unstructured":"Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633.","journal-title":"BMJ"},{"key":"5050_CR16","doi-asserted-by":"crossref","unstructured":"Xu M, Cao C, Wu P, Huang X, Ma D. Advances in cervical cancer: current insights and future directions. Cancer Commun (Lond). 2025;45(2).","DOI":"10.1002\/cac2.12629"},{"issue":"1","key":"5050_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41541-026-01426-8","volume":"11","author":"J Audouze-Chaud","year":"2026","unstructured":"Audouze-Chaud J, Schlosser AK, Riemer AB. The current landscape of therapeutic vaccination approaches for treatment of HPV-dependent malignancies. NPJ Vaccines. 2026;11(1):89.","journal-title":"NPJ Vaccines"},{"key":"5050_CR18","unstructured":"World Health Organization. WHO preferred product characteristics for therapeutic HPV vaccines. https:\/\/www.who.int\/publications\/i\/item\/9789240092174. Accessed 1 Feb 2025."},{"key":"5050_CR19","unstructured":"The Daffodil Centre. Mathematical modelling to assess the public health value and optimal attributes of a therapeutic HPV vaccine. Report. Accessed 1 Feb 2025."},{"issue":"5","key":"5050_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/ijc.33867","volume":"150","author":"JC Spencer","year":"2022","unstructured":"Spencer JC, Campos NG, Burger EA, Sy S, Kim JJ. Potential effectiveness of a therapeutic HPV intervention campaign in Uganda. Int J Cancer. 2022;150(5):847\u201355.","journal-title":"Int J Cancer"},{"issue":"9","key":"5050_CR21","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S2468-2667(19)30162-8","volume":"4","author":"C Xia","year":"2019","unstructured":"Xia C, Hu S, Xu X, Zhao X, Qiao Y, Broutet N, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. Lancet Public Health. 2019;4(9):e462\u201372.","journal-title":"Lancet Public Health"},{"issue":"1","key":"5050_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12916-021-01930-9","volume":"19","author":"C Xia","year":"2021","unstructured":"Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 2021;19(1):62.","journal-title":"BMC Med"},{"key":"5050_CR23","first-page":"101668","volume":"61","author":"F Zhao","year":"2025","unstructured":"Zhao F, Chen Q, Zhao C, Nie L, Hu S, Yin J, et al. Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16\/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort. Lancet Reg Health West Pac. 2025;61:101668.","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"5050_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2471\/BLT.11.097253","volume":"90","author":"A Binagwaho","year":"2012","unstructured":"Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda\u2019s national human papillomavirus vaccination programme. Bull World Health Organ. 2012;90(8):623\u20138.","journal-title":"Bull World Health Organ"},{"issue":"9","key":"5050_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.5694\/mja13.10272","volume":"199","author":"JM Brotherton","year":"2013","unstructured":"Brotherton JM, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013;199(9):614\u20137.","journal-title":"Med J Aust"},{"key":"5050_CR26","unstructured":"National Health Commission. Notice on issuance of action plan for accelerating cervical cancer elimination (2023\u20132030). https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/21\/content_5738364.htm. Accessed 1 July 2025."},{"issue":"41","key":"5050_CR27","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1016\/j.vaccine.2022.08.020","volume":"40","author":"HJ Prudden","year":"2022","unstructured":"Prudden HJ, Achilles SL, Schocken C, Broutet N, Canfell K, Akaba H, et al. Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022. Vaccine. 2022;40(41):5843\u201355.","journal-title":"Vaccine"},{"issue":"7","key":"5050_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"GY Ho","year":"1998","unstructured":"Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"5050_CR29","doi-asserted-by":"publisher","first-page":"e996","DOI":"10.1016\/S2468-2667(23)00186-X","volume":"8","author":"C Xia","year":"2023","unstructured":"Xia C, Basu P, Kramer BS, Li H, Qu C, Yu XQ, et al. Cancer screening in China: a steep road from evidence to implementation. Lancet Public Health. 2023;8(12):e996\u20131005.","journal-title":"Lancet Public Health"},{"issue":"3","key":"5050_CR30","first-page":"213","volume":"21","author":"H Yan","year":"2024","unstructured":"Yan H, Wang Q, Qiao Y. Cervical cancer prevention in China: where are we now, and what\u2019s next? Cancer Biol Med. 2024;21(3):213\u20137.","journal-title":"Cancer Biol Med"},{"issue":"10451","key":"5050_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024;404(10451):435\u201344.","journal-title":"Lancet"},{"issue":"1","key":"5050_CR32","doi-asserted-by":"publisher","first-page":"e2176009","DOI":"10.1080\/22221751.2023.2176009","volume":"12","author":"X Yang","year":"2023","unstructured":"Yang X, Li Y, Tang Y, Li Z, Wang S, Luo X, et al. Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. Emerg Microbes Infect. 2023;12(1):e2176009.","journal-title":"Emerg Microbes Infect"},{"issue":"10","key":"5050_CR33","doi-asserted-by":"publisher","first-page":"e29155","DOI":"10.1002\/jmv.29155","volume":"95","author":"J Yi","year":"2023","unstructured":"Yi J, Li X, Zhang R, Kong L, Wang Z, Yu Q, et al. The impact of the COVID-19 pandemic on the prevalence and genotype distribution of HPV infection in Beijing, China. J Med Virol. 2023;95(10):e29155.","journal-title":"J Med Virol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05050-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:03:15Z","timestamp":1791205395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5050"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05050-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YQ and FZ report grants from Gates Foundation, Merck & Co, and Xiamen Innovax Biotech to their institution, to undertake clinical trials on the human papillomavirus (HPV) vaccine. MJ reports receiving research grants from NIHR, RCUK, BMGF, WHO, Gavi, Wellcome Trust, European Commission, InnoHK, TFGH and CDC. MJ is an Editorial Advisor on BMC Medicine\u2019s Editorial Board. Other co-authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"539"}}